EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer

Yi-Yu Chen, Yi-Fan Zhou, Xuan Qi, Ya-Xin Zhao, Tong Fu, Xi Jin, Minhong Shen, Yi-Zhou Jiang iD, Zhi-Ming Shao iD

Advanced Science · 2026

DOI: 10.1002/advs.202518978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yi-Yu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai …. Hauptthemen laut MEDLINE: Killer Cells, Natural, Breast Neoplasms, Immunotherapy, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai, Clinical Research Plan of SHDC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy revolutionizes cancer therapeutics but shows limited efficacy in hormone receptor‐positive (HR + )/human epidermal growth factor receptor 2‐negative (HER2 − ) breast cancer. By leveraging large‐scale multi‐omics and single‐cell RNA sequencing (scRNA‐seq), we characterize the tumor microenvironment of HR + /HER2 − breast cancer, revealing that an abundance of activated natural killer (NK) cells correlates with favorable anti‐PD‐(L)1 responses. Our preclinical models demonstrate that immunotherapy enhances NK cell cytotoxicity and immunomodulatory functions, thereby impeding tumor growth. Furthermore, drug screening of cell lines and patient‐derived tumors reveals that platinum enhances NK cell cytotoxicity, potentially via the NF‐κB pathway, creating synergy with immunotherapy. Consistent with these findings, a clinical cohort analysis shows an increased proportion of activated NK cells in tumors following platinum‐based chemotherapy. Collectively, our study establishes the critical role of NK cells in mediating immunotherapy response in HR + /HER2 − breast cancer and uncovers a novel mechanism whereby platinum agents augment immunotherapeutic efficacy, offering a promising combination strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalBreast NeoplasmsImmunotherapyErb-b2 Receptor Tyrosine KinasesPlatinumHumansFemaleAnimalsTumor MicroenvironmentMiceLymphocyte ActivationCell Line, Tumor

Stichwörter der Autor:innen

HR+/HER2− breast cancerNK cellsimmune checkpoint inhibitorsimmunotherapyplatinum therapy

Substanzen

Erb-b2 Receptor Tyrosine KinasesPlatinumERBB2 protein, human

Autor:innen und Institutionen

  • Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
  • Shanghai Academy of Natural Sciences (SANS), Fudan University, Shanghai, China.

ORCID-Profile: Yi-Zhou Jiang, Zhi-Ming Shao

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shanghai
  • Clinical Research Plan of SHDC
  • Shanghai Rising-Star Program
  • Shanghai Anticancer Association EYAS PROJECT
  • Clinical Cohort Shanghai
  • Shanghai Oriental Talent Program
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Chen, Y. Y., Zhou, Y. F., Qi, X., Zhao, Y. X., Fu, T., Jin, X., Shen, M., Jiang, Y. Z., & Shao, Z. M. (2026). NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202518978

Vancouver

Chen YY, Zhou YF, Qi X, Zhao YX, Fu T, Jin X, et al. NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer. Advanced Science. 2026. doi:10.1002/advs.202518978

BibTeX
@article{Chen2026,
  author = {Chen, Yi-Yu and Zhou, Yi-Fan and Qi, Xuan and Zhao, Ya-Xin and Fu, Tong and Jin, Xi and Shen, Minhong and Jiang, Yi-Zhou and Shao, Zhi-Ming},
  title = {NK Cell Activation by Platinum Boosts Immunotherapy in HR + /HER2 − Breast Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202518978}
}
Kostenlos starten →